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Real-Time qPCR as a Tool for Evaluating RNAi-Mediated  
Gene Silencing
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To gain insight into the mechanism of action of MYCN and TP53 
genes in neuroblastoma pathogenesis, and to create a model 
system for future exploration of targeted therapeutics, we 
decided to exploit RNAi as an experimental tool for suppressing 
the expression of MYCN and TP53. The MYCN gene was 
transiently suppressed using several 27-mer siLentMer™* 
Dicer-substrate small interfering RNA (siRNA) duplexes, which 
are generally considered more effective at gene silencing than 
corresponding traditional 21-mer siRNAs (Kim et al. 2005). 
Stable knockdown of the TP53 gene was achieved using 
lentiviral-mediated short hairpin RNA (shRNA) interference.  
The CFX96™ real-time PCR detection system was used as a 
real-time detection platform.
Methods
Cell Lines
Human neuroblastoma cell lines IMR-32 and NGP carrying 
wild-type p53 were grown as a monolayer in RPMI-1640 
medium supplemented with antibiotics, 15% fetal calf serum, 
and 2 mM glutamine. Human embryonic kidney 293T cells 
were cultured in DMEM medium supplemented with antibiotics, 
10% fetal bovine serum, and 2 mM glutamine. All cells were 
incubated at 37°C in a humidified atmosphere containing  
5% CO2.
siRNA Transfections and Nutlin-3 Treatment
IMR-32 cells were transfected either with 10 nM of a 
nonspecific control siLentMer siRNA or siLentMer siRNAs 
targeting MYCN (target sequence of siRNA 1:  
5'-CGAGCTGATCCTCAAACGATGCCTTCC-3'; target sequence 
of siRNA 2: 5'-GACGCTGATACATAACTAAATTTGATA-3') in a 
6-well plate format using 2.5 µl of siLentFect™ lipid transfection 
reagent per well. Silencing efficiency was assessed by rt-qPCR 
48 hr after transfection. Nutlin-3 (Cayman Chemical) was 
dissolved in ethanol and stored at –20°C in small aliquots as  
a 10 mM stock solution. Cells were exposed to 0–32 µM of 
nutlin-3 for 24, 48, and 72 hr, with the final ethanol concentration 
kept constant in each experiment.
Lentiviral Vector Construction, Virus Production, and Infection
The sequence of the human TP53 gene that was targeted using 
shRNA was 5'-GACTCCAGTGGTAATCTAC-3'. As a negative 
control, we targeted the Trp53 gene, the murine form of p53, 
using the sequence: 5'-GTACTCTCCTCCCCTCAAT-3'. Pairs of 
complementary oligonucleotides containing these sequences 
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Introduction
Real-time quantitative PCR (rt-qPCR) is the method of 
choice for accurate, sensitive, and specific quantitation of 
nucleic acid sequences. Applications of this technology are 
numerous in molecular diagnostics and virtually all fields of life 
sciences, including gene expression profiling, measurement 
of DNA copy number alterations, genotyping, mutation 
detection, pathogen detection, measurement of viral load, 
disease monitoring, and assessment of drug response. 
Several factors, such as careful primer design and evaluation,  
template preparation, implementation of a robust normalization 
strategy, and accurate data analysis, are essential for a 
successful and reliable rt-qPCR assay. In this report we 
describe how rt-qPCR can be implemented as a tool for 
monitoring silencing efficiency and assessing functional effects  
of RNA interference (RNAi)-mediated knockdown of MYCN 
and TP53 genes, which are pivotal in neuroblastoma 
pathogenesis.
Neuroblastoma is a childhood cancer that is derived 
from precursor cells of the adrenosympathetic system, 
originating in the adrenal medulla or sympathetic ganglia. 
Three clinicogenetic subtypes of neuroblastoma can be 
discerned (Vandesompele et al. 2005), the most notorious 
being the subtype characterized by amplification of the 
MYCN oncogene. Amplification of MYCN is associated 
with advanced stage of disease and poor outcome, but the 
mechanisms by which this transcription factor exerts its 
oncogenic activity and confers an unfavorable prognosis 
are poorly understood. Another intriguing feature of 
neuroblastoma is the remarkably low frequency of TP53 
mutations upon diagnosis (Tweddle et al. 2003). We have 
previously shown that reactivation of the p53 pathway by 
the selective small-molecule MDM2 antagonist, nutlin-3, 
constitutes a promising novel approach for the treatment of 
neuroblastoma (Van Maerken et al. 2006). 
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were phosphorylated, annealed, and ligated into the pSIF-H1-
Puro vector (System Biosciences). The pSIF-H1-Puro vectors 
containing the shRNA sequences were cotransfected with 
two packaging plasmids (pFIV-34N and pVSV-G) (System 
Biosciences) into 293T cells using calcium phosphate 
precipitation. Viral supernatants, designated as LV-h-p53 
and LV-m-p53 for lentiviruses carrying the shRNA construct 
against human TP53 and murine Trp53, respectively, were 
collected and filtered through a 0.45 µm filter, and used to 
infect IMR-32 and NGP cells in the presence of 5 µg/ml 
polybrene (Sigma). Transduced cells were selected with  
1 µg/ml puromycin (Sigma) for 48 hr.
Quantitation of mRNA Expression by rt-qPCR
Total RNA was extracted from cells using the RNeasy  
mini kit (QIAGEN), with an on-column treatment with  
RNase-free DNase I. After an additional RQ1 DNase treatment 
in solution (Promega), first-strand cDNA was synthesized from 
2 µg total RNA using the iScript™ cDNA synthesis kit. Primer 
sequences for rt-qPCR analysis are available in the public 
RTPrimerDB database (http://medgen.ugent.be/rtprimerdb/) 
(Pattyn et al. 2006): GAPDH (ID #3), SDHA (ID #7),  
UBC (ID #8), MYCN (ID #180, P1; ID #3870, P2; ID #3871,  
P3; ID #3869, P4; ID #3868, P5), TP53 (ID #1186, P1;  
ID #3872, P2), MDM2 (ID #3499), and BBC3 (PUMA)  
(ID #3500). rt-qPCR assay validation was performed using 
RTPrimerDB’s in silico assay evaluation pipeline to determine 
specificity (BLAST), absence of secondary structure (mfold), 
and nucleotide polymorphisms in the primer annealing region.
In silico assay evaluation was followed by experimental 
evaluation of specificity and PCR efficiency using a standard 
curve consisting of six points of 4-fold serially diluted  
(64 ng down to 62.5 pg) reverse-transcribed human qPCR 
reference total RNA (Stratagene). (The protocol for generation 
of a template dilution series is available on http://medgen.
ugent.be/CMGG/protocols/). Relative mRNA expression levels 
were determined using an optimized two-step SYBR Green I 
rt-qPCR assay with minor modifications (Vandesompele 
et al. 2002a). The PCR was run in duplicate on the CFX96 
real-time PCR detection system in 15 µl reactions, containing 
7.5 µl of iQ™ SYBR® Green supermix, 250 nM of each 
primer, and cDNA equivalent to 20 ng of total RNA. Gene 
expression levels and PCR efficiency, along with its standard 
error, were calculated using the qBasePlus 1.0 analysis 
software (http://www.biogazelle.com) (Hellemans et al. 2007), 
which employs a proven delta-CT relative quantitation model 
with PCR efficiency correction and multiple reference gene 
normalization using GAPDH, UBC, and SDHA (Vandesompele 
et al. 2002b). 
Cell Viability Assay
Cells were seeded in duplicate in 96-well plates (1 x 104 cells/well) 
and incubated for 6 hr to permit adherence to the surface. 
Cells were then treated with 0–32 µM nutlin-3 for 24, 48, and 
72 hr. Cell viability was determined using the CellTiter-Glo 
luminescent cell viability assay (Promega). Three independent 
experiments were performed. 
Results and Discussion
From Experimental Design to Analysis of an rt-qPCR Assay
Bioinformatics-based quality assessment of newly designed 
rt-qPCR primers can considerably improve the likelihood of 
obtaining specific and efficient primers. A number of quality 
control parameters have been integrated in our in-house 
developed RTPrimerDB’s in silico assay evaluation pipeline 
(Pattyn et al. 2006) that allow for a streamlined assessment 
of candidate primer pairs, with automated BLAST specificity 
search, prediction of putative secondary structures of the 
amplicon, indication of which transcript variants of the gene 
of interest will be amplified, and search for known SNPs in the 
primer annealing regions. This in silico evaluation, however, 
does not preclude the need of experimental validation after 
synthesis of the primers. Ideally, experimental evaluation 
addresses specificity, efficiency, and dynamic range of the 
assay using a broad dilution series of template (Figure 1).
Purity and integrity of the RNA template are critical factors 
to the success of an rt-qPCR assay. Several kits are 
commercially available for producing clean RNA samples. 
Contaminants should be avoided or removed, since they can 
greatly influence the reverse transcription step or the actual 
PCR. The presence of PCR inhibitors can be assessed using 
a variety of methods, including the simple and fast PCR-
based SPUD assay (Nolan et al. 2006a). An oligonucleotide 
target sequence with no homology to human DNA is spiked 
into human RNA samples and a water control at a known 
concentration. rt-qPCR quantitation of the oligonucleotide 
template in both the RNA samples and the (negative) water 
control is indicative of possible enzymatic inhibitors present 
in the RNA extract. For assessment of RNA integrity, 
electrophoresis and PCR-based methods are available  
(Fleige and Pfaffl 2006, Nolan et al. 2006b).
To control for inevitable experimental differences due to 
variables such as the amount and quality of starting material, 
enzymatic efficiencies, and overall cellular transcriptional 
activity, use of a reliable normalization strategy in which these 
factors are taken into account is necessary. In principle, 
internal reference genes offer the best way to deal with the 
multiple sources of confounding variables that might exist 
between different samples. A truly accurate normalization can 
be achieved only when multiple reference genes are utilized, 
since use of a single reference gene results in relatively 
large errors in a considerable proportion of the sample set 
(Vandesompele et al. 2002b). Because no universal set of 
reference genes exists, care should be taken when selecting 
the genes to be used for normalizing the expression levels. 
Different sample origins and experimental manipulations 
might require another set of genes to be used as reference 
genes. Selection and validation of reference genes can be 
done using the geNorm algorithm, which determines the most 
stable genes from a set of tested candidate reference genes 
in a given sample panel and calculates a normalization factor 
(Vandesompele et al. 2002b).
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Processing and analysis of the raw rt-qPCR data represent 
a multistep computational process of averaging replicate 
CT values, normalization, and proper error propagation 
along the entire calculation track. This process might prove 
cumbersome and deserves equal attention as the previous 
steps in order to get accurate and reliable results. This 
final procedure has been automated and streamlined in 
Biogazelle’s qBasePlus software, a dedicated program  
for management and analysis of rt-qPCR data (Hellemans  
et al. 2007).
Assessment of siRNA Silencing Efficiency Using rt-qPCR in 
Cells Treated With Anti-MYCN siLentMer siRNA Duplexes 
Human IMR-32 neuroblastoma cells were transfected 
with different anti-MYCN siLentMer siRNA duplexes or a 
nonspecific control siRNA, and the level of MYCN transcript 
was determined 48 hr posttransfection by rt-qPCR. Our 
results show variable levels of MYCN silencing with different 
primers (Figure 2A), which indicates the importance of primer 
location for evaluation of siRNA silencing efficiency, consistent 
with a previously published study (Shepard et al. 2005). 
The target mRNA sequence is cleaved by the RNA-induced 
silencing complex (RISC) near the center of the region 
complementary to the guiding siRNA (Elbashir et al. 2001). 
Complete nucleolytic degradation of the resulting fragments is 
not always guaranteed, which might result in underestimation 
of siRNA silencing efficiency if primers that do not span the 
siRNA target sequence are used for rt-qPCR (Figure 2B). 
Evaluation of Silencing Efficiency and Functional Effects of 
Lentiviral-Mediated shRNA Knockdown of TP53 Using rt-qPCR
To generate stable TP53 knockdown variants of 
neuroblastoma cell lines that carry wild-type p53, we infected 
IMR-32 and NGP cells with a lentiviral vector encoding an 
shRNA directed specifically against the human TP53 gene 
(LV-h-p53) or against the murine Trp53 gene (LV-m-p53), as 
Fig. 1. Experimental validation of newly designed rt-qPCR primers.  
A, PCR efficiency and dynamic range of the rt-qPCR assay was tested  
using a 4-fold serial dilution of six points of reverse transcribed human  
qPCR reference total RNA (64 ng down to 62.5 pg) and TP53 P2 primers;  
B, specificity of the TP53 P2 primers was assessed by generating a melting 
curve of the PCR product; C, standard curve and PCR efficiency estimation 
(including the error) according to the qBasePlus software. Cq, quantitation 
cycle value.
Fig. 2. Importance of primer location for rt-qPCR assessment of siRNA 
silencing efficiency. A, percentage silencing of MYCN gene expression 
measured by five different primer pairs (P1–P5) in IMR-32 cells 48 hr after 
transfection with anti-MYCN siLentMer siRNA duplexes (siRNA 1 or siRNA 2), 
compared to cells transfected with a nonspecific control siRNA; B, schematic 
representation of the MYCN mRNA structure with location of siRNA-targeted 
sequences and primer binding sites. 
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a negative control. rt-qPCR analysis with two different primer 
pairs demonstrated that expression of TP53 was reduced 
by 81–87% in IMR-32 cells infected with LV-h-p53 and by 
92–94% in NGP cells infected with LV-h-p53, compared to 
the respective control cells infected with LV-m-p53 (Figure 3).
Functionality of the TP53 knockdown variants was validated 
by rt-qPCR and analysis of cell viability after treatment with 
nutlin-3. This small-molecule compound selectively disrupts 
the interaction between p53 and its negative regulator MDM2, 
resulting in stabilization and accumulation of the p53 protein 
and activation of the p53 pathway (Vassilev et al. 2004).
Lentiviral-mediated expression of shRNA against human TP53 
prevented transactivation of p53 target genes, such as BBC3 
(PUMA) and MDM2, by nutlin-3 (Figure 4A, B). In addition, 
downregulation of TP53 transcript level by nutlin-3, a result 
of the ability of the p53 protein to negatively autoregulate its 
transcriptional expression after accumulation (Hudson et al. 
1995), was abrogated in cells infected with LV-h-p53 (Figure 
4C, D). At the cellular level, silencing of human TP53 severely 
attenuated the cell viability response to nutlin-3 (Figure 5A,  
B, D, E), in contrast to control infection with LV-m-p53  
(Figure 5A, C, D, F), while viability of nontransduced parental 
cells (Figure 5A, D) and cells infected with LV-m-p53 (Figure 
5C, F) was significantly reduced when treated with increasing 
Fig. 3. Assessment of shRNA-mediated TP53 knockdown efficiency by 
rt-qPCR. IMR-32 and NGP cells were infected with a lentivirus carrying an 
shRNA construct specific for either the human TP53 gene (LV-h-p53) or the 
murine Trp53 gene (LV-m-p53) as a control. Efficiency of TP53 gene silencing 
was evaluated by rt-qPCR using two different primer pairs (TP53 P1 and  
TP53 P2). Bars indicate mRNA expression levels of TP53, relative to the  
respective LV-m-p53 infected cells; error bars depict standard error of the 
mean (duplicated PCR reactions for TP53 and 3 reference genes).
Fig. 4. Functional validation of shRNA-mediated TP53 knockdown through 
rt-qPCR analysis of transcript levels of p53-regulated genes after  
nutlin-3 treatment. IMR-32 and NGP cells were infected with a lentiviral vector 
encoding an shRNA directed specifically against either the human TP53 gene 
(LV-h-p53) or the murine Trp53 gene (LV-m-p53). Cells were treated with 0, 8,  
or 16 µM nutlin-3 for 24 hr, and expression of BBC3 (PUMA) (A), and MDM2 (B), 
p53-regulated genes, and TP53 was determined by rt-qPCR. Two different  
primer pairs (TP53 P1 and TP53 P2) were used for quantification of TP53  
transcript levels (C, D). Bars indicate mRNA expression levels relative to the 
respective vehicle-treated (0 µM nutlin-3) LV-m-p53 infected cells, mean of two 
different rt-qPCR measurements; error bars show standard error of the mean. 
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concentrations of nutlin-3. These results firmly demonstrate 
potent and selective impairment of p53 function in IMR-32 
and NGP cells infected with a lentivirus carrying an shRNA 
construct against human TP53.
Fig. 5. Functional validation of shRNA-mediated TP53 knockdown through cell viability analysis after treatment of IMR-32 and NGP cells with nutlin-3. 
Effect of nutlin-3 on viability of uninfected cells (A, D), LV-h-p53 infected cells (B, E), and LV-m-p53 infected cells (C, F). Exponentially growing cells were exposed to 
0–32 µM of nutlin-3 for 24, 48, and 72 hr, and the percentage cell viability, with respect to vehicle-treated (0 µM nutlin-3) cells, was determined. Error bars indicate 
standard deviation of mean cell viability values of three independent experiments. 
Conclusions
rt-qPCR analysis provides a convenient and reliable method 
for evaluating knockdown efficiency and functional effects of 
RNAi-mediated gene silencing, as demonstrated by the use 
of this tool for monitoring knockdown of MYCN and TP53 
genes, which are pivotal in neuroblastoma pathogenesis. 
Successful application of rt-qPCR requires careful attention to 
all of the steps in the assay workflow, including primer design 
and evaluation, template preparation, normalization strategy, 
and data analysis.
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